- TheStreet.com•1 hour ago
As consumer confidence and health care spending soar, Johnson & Johnson is becoming one of the best total return packages available.
- American City Business Journals•2 hours ago
The Food and Drug Administration approved expanding the label for Horsham-based Janssen Biotech’s Stelara product to include its use for the treating Crohn's disease. Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract that affects about 700,000 Americans. The FDA approval of Stelara specified its use in adults 18 or older with moderately to severely active Crohn’s disease who have failed, or were intolerant to, treatment with immunomodulators or corticosteroids, but who never failed treatment with a tumor necrosis factor blocker.
Johnson & Johnson (JNJ)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||119.44 x 400|
|Ask||119.45 x 200|
|Day's Range||118.81 - 119.52|
|52wk Range||91.76 - 126.07|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||22.25|
|Avg Vol (3m)||6,432,098|
|Dividend & Yield||3.20 (2.72%)|